Cyanopyrroles

US6562857B2 · kind B2 · utility

Assignee

• Wyeth, LLC · US

Inventors

• Mark A. Collins · Norristown, US
• Valerie A. Mackner · Conshohocken, US
• Jay E. Wrobel · Lawrenceville, US
• Lin Zhi · San Diego, US
• Todd K. Jones · Solana Beach, US
• James P. Edwards · San Diego, US
• Christopher M. Tegley · Thousand Oaks, US

Key dates

• Filing date: Jan 9, 2002
• Grant date: May 13, 2003
• Expiry date: Jan 9, 2022

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D413/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention provides a progesterone receptor agonist of formula 1 having the structure wherein T is O, S, or absent; R1, and R2 are each, independently, hydrogen, alkyl, substituted alkyl; or R1 and R2 are taken together form a ring and together contain —CH2(CH2)nCH2—, —CH2CH2CMe2CH2CH2—, —O(CH2)pCH2—, —O(CH2)qO—, —CH2CH2OCH2CH2—, or —CH2CH2NR7CH2CH2—;n=1-5; p=1-4; q=1-4;R3 is hydrogen, OH, NH2, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, or CORA;RA is hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aminoalkyl, or substituted aminoalkyl;R4 is hydrogen, halogen, CN, NH2, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aminoalkyl, or substituted aminoalkyl;R5 is hydrogen, alkyl, or substituted alkyl;R6 is hydrogen, alkyl, substituted alkyl, or CORB,RB is hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aminoalkyl, or substituted aminoalkyl;R7 is hydrogen or alkyl; or a pharmaceutically acceptable salt thereof